Posts

Transthyretin Amyloidosis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Transthyretin Amyloidosis Emerging Therapy and TPP Insights Thelansis’s “Transthyretin Amyloidosis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Transthyretin Amyloidosis Overview Transthyretin amyloidosis (ATTR amyloidosis) is a progressive, life-threatening systemic disease caused by misfolding and aggregation of transthyretin protein into amyloid fibrils depositing in multiple organs, occurring in hereditary form driven by pathogenic TTR gene mutations and wild-type form arising from age-related TTR instability, predominantly affecting the heart and peripheral nervous system. Cardiac involvement produces restrictive cardiomyopathy with preserved ejection fraction, progressive heart failure, conduction abnormalities, and arrhy...
Post a Comment
Read more

Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Emerging Therapy and TPP Insights Thelansis’s “Chemotherapy-Induced Peripheral Neuropathy (CIPN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and often dose-limiting toxicity resulting from neurotoxic antineoplastic agents, most notably taxanes, platinum compounds, and vinca alkaloids. Pathogenesis involves multifaceted damage to the peripheral nervous system, including axonal degeneration, mitochondrial dysfunction, and direct injury to the dorsal root ganglia, which are vulnerable due to high metabolic activity and a permeable blood-nerve barrier. Clinically, C...
Post a Comment
Read more

Primary Biliary Cholangitis (PBC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Primary Biliary Cholangitis (PBC) Emerging Therapy and TPP Insights Thelansis’s “Primary Biliary Cholangitis (PBC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Primary Biliary Cholangitis (PBC) Overview Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune cholestatic liver disease characterised by immune-mediated destruction of small intrahepatic bile ducts, driven by autoreactive T-cell targeting of mitochondrial antigens — predominantly the pyruvate dehydrogenase complex E2 subunit — in genetically susceptible individuals, with antimitochondrial antibodies (AMA) serving as the hallmark diagnostic biomarker present in over 90% of patients. Predominantly affecting middle-aged women, patients may prese...
Post a Comment
Read more

Neuroendocrine Tumors (NETs) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Neuroendocrine Tumors (NETs) Emerging Therapy and TPP Insights Thelansis’s “Neuroendocrine Tumors (NETs) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Neuroendocrine Tumors (NETs) Overview Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms arising from secretory cells of the diffuse neuroendocrine system, occurring most commonly in the gastroenteropancreatic tract and lungs, characterised by variable hormonal secretory activity and somatostatin receptor overexpression. Well-differentiated NETs are graded G1 through G3 by Ki-67 proliferative index, while poorly differentiated neuroendocrine carcinomas represent a distinct aggressive entity. Functioning tumors produce hormonal syndromes including carcinoid syndrome, ins...
Post a Comment
Read more

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Therapy and TPP Insights Thelansis’s “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview Chronic Inflammatory Demyelinating Polyneuropathy is an immune-mediated peripheral neuropathy driven by T-cell and autoantibody-mediated myelin destruction, causing progressive or relapsing proximal and distal limb weakness with sensory impairment. Patients present with symmetric weakness, areflexia, gait instability, and sensory disturbance evolving over months. Diagnosis combines nerve conduction studies showing demyelination, CSF cytoalbuminous dissociation, and n...
Post a Comment
Read more

Charcot-Marie-Tooth (CMT) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Charcot-Marie-Tooth (CMT) Emerging Therapy and TPP Insights Thelansis’s “Charcot-Marie-Tooth (CMT) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Charcot-Marie-Tooth (CMT) Overview Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, encompassing a clinically and genetically heterogeneous group of disorders caused by mutations across numerous genes regulating peripheral nerve myelination and axonal integrity — most prevalently PMP22 duplication causing CMT1A, GJB1 mutations causing X-linked CMTX, and MPZ and MFN2 mutations underlying demyelinating and axonal subtypes respectively. The pathophysiology involves either primary Schwann cell and myelin dysfunction — producing demyelinating CMT1 subtypes with...
Post a Comment
Read more

Essential Tremor (ET) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Essential Tremor (ET) Emerging Therapy and TPP Insights Thelansis’s “Essential Tremor (ET) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Essential Tremor (ET) Overview Essential tremor (ET) is one of the most common adult movement disorders, characterized as a chronic, progressive neurological condition manifesting primarily as a symmetric kinetic and postural tremor. It predominantly affects the upper extremities, though the head, voice, and lower limbs can be involved. Unlike Parkinson’s disease, the tremor is typically absent at rest and worsens during voluntary, goal-directed movements, significantly impairing activities of daily living like writing, eating, and drinking. Pathophysiology is linked to dysfunction wit...
Post a Comment
Read more